07.03.2017 • NewsDede WillamsDSMDyneema

DSM Dyneema Wins Israeli Patent Case

(c) StudioSmart/Shutterstock
(c) StudioSmart/Shutterstock

In the final instance,  DSM Dyneema has won a protracted patent challenge against publicly held FMS Enterprises Migun of Tel Aviv. The firm had attempted to block the Dutch manufacturer of Dyneema, claimed to be the world’s strongest fiber, from obtaining a patent for the product in Israel.

An Israeli district court has now upheld an earlier decision of the Israeli Patent Office dismissing FMS’ claims.

DSM said the decision clears the way for the grant of a patent to Dyneema for the ultra-high molecular weight polyethylene (UHMWPE) fiber that specifies the amount of solvent to be used and acknowledges its rights to the relevant production technology. The fibers are claimed to improve the performance of end-use applications including ropes and ballistic-resistant products.

The Israeli decision is in-line with the grant of corresponding patents to DSM Dyneema in other global jurisdictions, such as the US, China and Europe, said Golnar Motahari Pour, president of the DSM subsidiary.

“Innovation and patents are cornerstones of DSM Dyneema’s business strategy,” Motahari Pour said, adding that the company has” consistently and rigorously defended its intellectual property on many occasions, and will continue to do so.” 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.